

2 October 2024

Investor Presentation

Bio-Gene Technology Limited (ASX: BGT, 'Bio-Gene' or the 'Company'), an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance, is pleased to provide an updated non-confidential corporate presentation for shareholders and investors.

This presentation contains an overview of the Company's strategy, pipeline, product development path and recent milestones. It will be used in various upcoming investor and shareholder meetings.

Approved for release by the Board of Directors.

~ ENDS ~

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance. Its unique products are based on a naturally occurring class of compounds proven to overcome resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited in Australia.

Bio-Gene Technology Limited

ABN: 32 071 735 950

Level 6, 400 Collins Street, Melbourne, VIC 3000

For personal use only

For personal use only

Investor Presentation

Developing new insecticides derived from nature to achieve high impact worldwide.

October 2024



Important Notice & Disclaimer

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. No representation, warranty or guarantee, express or implied, is given that any Forward-Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward-Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

Contents



For personal use only

Investment Highlights 04.

Market Overview 06.

Product Overview 08.

Commercial Strategy 09.

Key Metrics & Milestones 14.

Investment Highlights

Focused development of two new insecticides with strong commercial validation.

For personal use only

01. Two New Actives

Late-stage development: two insecticidal compounds **derived from nature with novel modes of action:**

- » **Flavocide®** and **Qcide®** are derived from a unique sub-type of eucalypt
- » effectiveness against some major insect pests with resistance to standard products
- » Strong drivers are increasing the demand for **safer and more environmentally friendly** products

02. Large Target Markets

Crop Protection (incl. Grain Storage), **Public Health**, **Consumer**, **Animal Health**, total addressable markets of \$31B, as **both stand-alone and combination** products¹

03. Focused Pipeline

Pipeline of eight (formulated) product opportunities:

- » Public Health – vectors for disease
- » Crop Protection, Aquaculture, Professional Turf and Ornamentals
- » Grain Storage Protection
- » Consumer (home & garden)

04. Strong Partnering Progress

Three partnerships to date:

- » Clarke Mosquito (US), Evergreen Garden Care (EU, UK, AU & NZ), STK (Israel)

1. US EPA 2017, WHO 2017, Zoetis & Provue Market Research, Markets & Markets
 2. Qcide® and Flavocide® are registered trademarks of Bio-Gene Technology Limited.



Experienced Board of Directors & Management Team

A team with strong experience in product development, partnering and commercialisation.

For personal use only



Alex Ding
Chairman

Previously partner at two law firms and expert in M&A, capital markets, and general corporate law.



Andrew Guthrie
Non-Executive Director

32 years' experience in agriculture globally, formerly a member of Syngenta's leadership team.



Tim Grogan
MD & CEO

30 years' experience growing companies in the agtech, food and human health sectors.



Edmond Tern
CFO & Company Secretary

30 years' experience as CFO and across both listed and unlisted companies.



Chris Ramsey
Non-Executive Director

Over 30 years' experience in agriculture business start up, development, marketing & agronomy.



Peter May
Executive Director R&D

Over 30 years' experience in crop protection market.



Dr James Wade
Program Manager

PhD with 10+ years experience in research in a broad range of agricultural verticals.



Richard Jagger
Commercial Advisor (Business Development)

25+ years in agriculture.

The Global Challenges We Help Solve

Our products address the demand for effective pest control & sustainable agriculture.

For personal use only

Public Health Vector Control



The mosquito is “the world’s deadliest animal”¹

- » Causes more human deaths than any other creature on earth
- » 247 million malaria cases in 2021, in 84 malaria endemic countries²
- » Between 2019 - 20 malaria deaths increased by 10% to 625,000³
- » Over 32,000 cases of Dengue recorded in Singapore in 2022⁴

1. US Centers for Disease Control and Prevention
2. Global expansion and redistribution of Aedes-borne virus transmission risk with climate change, S.J. Ryan et. al
3. World Malaria Report 2022
4. NEA Launches National Dengue Prevention Campaign Early To Urge Continued Vigilance And Avert A Dengue Outbreak In 2023
5. Savary, S., Willocquet, L., Pethybridge, S.J. et al. The global burden of pathogens and pests on major food crops. Nat Ecol Evol 3, 430–439 (2019)
6. ‘The current and potential costs of invertebrate pests in grain crops’, GRDC
7. 2024 CropLife magazine Biologicals online survey, The state of US crop biologicals in 2024 (agfundernews.com)

Crop Protection



Pesticides are critical to farming

- » 20-40% of global food production lost to pests - est. US\$2 trillion per year⁵ and increasing - due to:
 - growing insect resistance to current insecticides
 - climate change
 - increased population pressures
- » The estimated annual losses for the six major Australian grain crops due to invertebrate pests is est. A\$360M⁶
- » CropLife’s US survey found that 72% of respondents “are planning to increase the number of biological products their companies sell to grower-customers during the coming year”

The Global Challenges We Help Solve

Meeting the increasing market demands for safe and effective pest control solutions and new modes of action.

For personal use only



A *diminishing pool of available products* for farmers and public health officials:

- » Insects' resistance to insecticides
- » Loss of approved registrations for traditional chemistries



Bio-Gene is developing two active ingredients, Qcide and Flavocide, *derived from nature* that control insect pests using *a novel mode of action*.



Bio-Gene's two new active compounds have *proven synergy* with some key insecticide groups, meaning the overall efficacy and safety profile may be improved and the patent life of these current products may be extended when combined with Qcide and Flavocide.



Our Unique Products Derived from Nature

Qcide®

Qcide is an 100% natural oil extracted from the leaves of a specific cultivar of eucalypt (*Gypmie messmate*) currently farmed in northern Australia.


- ✓ *12th harvest in QLD completed in 2024*

Flavocide®

Flavocide is based on flavesone, a naturally occurring plant compound synthesised via a proprietary process that allows production in large volumes for global demand.

- ✓ *Pilot-scale production completed at Rallis India Ltd*






Patent families owned by Bio-Gene include: (1) Control of resistant pests.(2) Use in synergistic combinations, (3) Control of specific pests e.g., aphids, (4) Ovicidal activity against insect pests e.g., mites, bed bugs. Territories: Australia & New Zealand, USA/Europe, Latin America (Brazil), Asia (China), Africa (RSA)



Flavocide & Qcide – Multiple Market Segments

Bio-Gene is targeting five large well-developed global markets

For personal use only








Sectors					
	Crop Protection	Grain Storage	Public Health	Consumer Applications	Animal Health
	Food & Fibre	Stored Grain	Vector Control for Malaria, Zika & Dengue	Urban Pest Management, Oils, Lotions & Personal Repellents	Livestock & Pet-care Products
Size (US\$) & % of \$31.1B	\$16.1B 52%	\$1.0B 3%	\$4.0B 13%	\$4.1B 13%	\$5.9B 19%
Current Products & Challenges	<p>EU import restrictions (e.g. Omethoate for red-legged earth mite in Canola)</p> <p>Secondary regulation imposed by food chain (Aldi)</p> <p>Consumer and regulatory pressures</p>	<p>Pyrethroids, phosphine, organophosphates, etc.</p> <p>High levels of resistance in lesser grain borer, flat grain beetle, rice weevil</p>	<p>e.g. Bifenthrin, deltamethrin, pyrethrins, etc.</p> <p>Mosquito control market projected to grow by 38% between 2021-26¹</p>	<p>Mineral oils, toxic synthetics (e.g. malathion), pyrethum based products etc.</p> <p>Home and garden uses, Shift towards safe (especially to children & pets) and eco-friendly products to protect the environment</p>	<p>Japanese Encephalitis outbreaks</p> <p>Prevalence of ticks</p> <p>Consumer concerns for pet health</p>

1. Global Mosquito Control Professional Survey Report 2021, Forecast to 2026)

Flavocide & Qcide – Multiple Market Segments

Bio-Gene is targeting five large well-developed global markets

For personal use only


Active constituent	Description	Sectors	Target uses	Partners & Collaborators
Flavocide	1 Grain Protectant	Crop protection	Admixture to grain	
	2 Outdoor Space Spray	Public health	Flying insects	
	3 Indoor Barrier Spray	Public health	Flying & crawling insects	
	4 Outdoor Barrier Spray	Public health	Flying & crawling insects	
	5 Indoor Space Spray	Consumer	Flying insects	
Qcide	6 Indoor Space Spray	Consumer	Flying insects	
	7 Outdoor Barrier Spray	Consumer	Flying insects	
	8 Outdoor Garden Spray	Crop protection & Consumer	Fruit & vegetables, ornamentals	 

BGT is also investigating other potential use patterns, product extensions and combinations with other active ingredients.

Flavocide Development Path

Regulatory approval of a formulated product is a two-step process.

For personal use only



* Timeline based on current estimates.

★ Key inflection milestones that will generate increased revenue and interest from commercial partners

Multiple Commercial Partnerships in Place

Bio-Gene has established commercial partnerships with global partners, with additional commercial partners in progress.



For personal use only

		
<p>Applies advanced botanical science to the development & commercialisation of natural crop protection for growers worldwide</p>	<p>Clarke is the largest vertically integrated company in public health mosquito control in the US</p>	<p>Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand</p>
<p>Develop, register and commercialise Qcide for crop protection</p>	<p>Develop, register and commercialise Flavocide for public health and residential mosquito control in US and Cayman Islands</p>	<p>Develops and registers products for consumer applications across Europe, UK, Australia and NZ</p>
<p>Revenue Model</p> <ul style="list-style-type: none"> » Active ingredient supply to STK » On-going royalties on end-use product sales with other commercial partners 	<p>Revenue Model</p> <ul style="list-style-type: none"> » Up-front license fee » Milestone payments prior to registration » On-going royalties on end-use product sales » Commercial supply of Flavocide active ingredient to Clarke » Formulated product development costs borne by Clarke 	<p>Revenue Model</p> <ul style="list-style-type: none"> » Up-front license fee » Milestone payments prior to registration » On-going royalties on end-use product sales » Commercial supply of Flavocide active ingredient » Formulated product development costs borne by Evergreen

Key Collaborations Snapshot

R&D partnerships advance development and registration of Qcide and Flavocide.

For personal use only

	<p>Envu was founded in 2022 from Bayer’s environmental science division. Envu’s product pipeline focuses on novel, safe and environmentally-friendly insecticides</p> <ul style="list-style-type: none"> » Evaluating Flavocide as a commercial insecticide for use in mosquito control products
	<p>Runs an internationally recognised research program focused on new, human safe insecticides for control of insects and ticks</p> <ul style="list-style-type: none"> » Flavocide included in major US CDC US\$10m funded program on tick-borne diseases.
	<p>An Australian Government statutory authority investing in research development and extension for grain growers</p> <ul style="list-style-type: none"> » Supports Bio-Gene to develop and register Flavocide for use in grain storage.
	<p>Australia’s national science agency</p> <ul style="list-style-type: none"> » Assisting to develop and optimise the method of producing Flavocide.




Capital Structure

For personal use only

Key metrics (26 September 2024)

ASX code	BGT
Share price	\$0.045
Market Capitalisation	~A\$9m
Shares on issue	201,361,570
Cash (30 June 2024)	A\$2.21m



Recent Milestones & News flow

For personal use only

8 August 2024

Study plans for Flavocide on track following APVMA feedback

ASX ANNOUNCEMENT
8 August 2024

BIO-GENE
TECHNOLOGY
LTD

Bio-Gene's registration plans for Flavocide® on track following APVMA feedback

Highlights

- Studies planned for the Flavocide® insect control active ingredient regulatory dossier are confirmed following feedback received from the Australian Pesticides and Veterinary Medicines Authority (APVMA)
- APVMA provides assistance on the regulatory requirements to facilitate registration of new active ingredients
- Flavocide is a novel insecticidal active ingredient derived from nature being developed by Bio-Gene for use in public health, agriculture and by consumers



Australian Government
Australian Pesticides and Veterinary Medicines Authority

14 August 2024

Envu collaboration to evaluate Flavocide for mosquito management



ANNOUNCEMENT
14 August 2024

Bio-Gene and Envu collaborate to evaluate Flavocide™ for use in public and private sector mosquito management

Highlights

- Joint collaboration evaluating Flavocide™ for mosquito management across a range of professional applications
- Flavocide complements the product pipeline of forward-thinking effective chemistries Envu offers for the global professional non-crop market
- Flavocide shown to effectively control mosquitoes

2 September 2024

Flavocide production successful at pre-commercial scale



ASX ANNOUNCEMENT
2 September 2024

Bio-Gene and Rallis India Limited achieve key Flavocide® production milestone


Highlights

- Successful pilot-scale production of Flavocide® conducted by Rallis India Limited, one of India's leading Agri-sciences companies and a subsidiary of Tata Chemicals Limited
- Demonstration that Flavocide® can be produced at a consistent quality and yield at precommercial scale
- Flavocide® produced by Rallis India Limited to be used in planned testing activities to advance the registration process for Flavocide®
- Capacity to produce Flavocide® in sufficient quantities for future supply to Bio-Gene's commercial licensees

Bio-Gene's Strategic Priorities

Strategy is focused on efficient development and approval of Flavocide and Qcide, with more commercial partnerships.

For personal use only



Speed

Particularly the pre-registration manufacturing and safety studies for Flavocide and Qcide active ingredients.

Efficient Use of Capital

To leverage the funding from shareholders wherever possible with partner contributions and grants.

Commercial Validation

To build on existing commercial partnerships and secure the resources of additional larger partners and funding organisations to support the development of additional commercially attractive botanically derived insecticides.

Focused Product Development

To deploy our resources against a pipeline of the most commercially attractive development products and partnered programs (both as stand-alone and combination products) that can be developed as soon as possible.

Key Forward Milestones & News Flow

Bio-Gene has many catalysts to drive value over the next 18 months, with a strong pipeline of near-term news flow.

For personal use only

01

Flavocide & Qcide development

- ✓ Flavocide regulatory studies (multiple)
- ✓ Submission of Flavocide regulatory dossier in Australia
- ✓ Flavocide scale-up milestones
- ✓ Qcide regulatory development milestones
- ✓ Qcide scale-up and harvest/processing progress
- ✓ Regulatory milestones

02

Partnering & commercial

- ✓ New commercial partnerships
 - Crop & grain storage
 - Vector control
 - Consumer uses
- ✓ Expansion of current licenses
- ✓ Receipt of milestone payments
- ✓ Patents granted

03

Funding & other support

- ✓ Grant funding successes
- ✓ Synergistic program/product opportunities
- ✓ International funding support & validation

Investment highlights

Bio-Gene is targeting five large well-developed global markets

For personal use only

Bio-Gene is developing *two naturally derived* insecticidal active ingredients, overcoming resistance by controlling pests via a *novel mode of action*

Substantial market opportunity with growing need, given resistance, for novel solutions

Strong third-party validation with current partnerships and development partners



High margin business model with significant operating leverage

Experienced management team and board focused on execution of strategy and generating returns

For personal use only

Contact

Tim Grogan
Managing Director & CEO
timg@bio-gene.com.au

Matthew Wright
NWR Communications
matt@nwrcommunications.com.au
0451 896 420

